MarketPulse
I

$INMB

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Inmune Bio Inc.

INmune Bio Slashes Losses 44% in Q1 2026 While Advancing Alzheimer's Pipeline

INmune Bio reported Q1 2026 net loss of $5.4M, down from $9.7M year-ago. Company advancing XPro for Alzheimer's with $21.4M cash on hand.
INMBclinical trialsQ1 2026 earnings
GlobeNewswire Inc.GlobeNewswire Inc.··Na

INmune Bio to Unveil Q1 2026 Results Amid Clinical-Stage Immunology Development

$INMB will report Q1 2026 financials May 7th, providing updates on its three immunology product platforms targeting inflammation and innate immune disorders.
INMBconference callclinical-stage biotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Inmune Bio Inc.

INmune Bio's Alzheimer's Trial Wins Spotlight as Model for Inflammation-Targeting Approach

INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.
INMBclinical trialAlzheimer's disease